Thoracic Neoplasms Clinical Trial
Official title:
Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High Risk Patients (SELEPREBB1)
The goal of this multicentric French randomized trial is to determine the best auto
fluorescence bronchial endoscopic follow-up strategy in high risk patients bearing low grade
bronchial precancerous lesions. Subjects will be randomly assigned to one of the following
arm :
(A) every 6 months clinical and chest Xrays follow-up without intermediate endoscopy, (B)
every 6 months clinical and chest Xrays follow-up including repeated autofluorescence
endoscopy and biopsies on a 6 months basis in case of low grade dysplasia or on a one year
basis in patients without dysplasia.
After 36 months follow-up, each patient from the two groups will be subjected to a final
autofluorescence endoscopy and biopsy and a Spiral Chest Xray.
The final analysis will compare between the two groups :
1. The probability of progression from an initially identified low grade lesion to a high
grade lesion
2. The probability of respiratory epithelial tract progression assessed by the occurrence
of a lung cancer or high grade lesion.
3. The characteristics of lung cancers detected in each arm
4. In both arm, the influence of risk factors and persistent exposure to tobacco on lesion
evolutivity.
The goal of this multicentric French randomized trial is to determine the best auto
fluorescence bronchial endoscopic follow-up strategy in high risk patients bearing low grade
bronchial precancerous lesions. This Trial compares two follow-up modalities : observation
without endoscopy for a three year period (group A " light " follow-up), versus repeated
autofluorescence endoscopies and biopsies every six months for three years (group B "
intensive ").
Methods: 300 subjects at high risk for lung cancer will be included over a two year period
and followed-up for three years. In each subject an auto-fluorescence endoscopy and a Chest
CT scan will be performed before the enrollment into the trial. To be included the subject
must present with an initial Chest CT scan not suspicious for lung cancer and bronchial
biopsy showing a moderate dysplasia or a lower grade lesion.
Subjects will be randomly assigned to one of the following arm :
(A) every 6 months clinical and chest Xrays follow-up without intermediate endoscopy, (B)
every 6 months clinical and chest Xrays follow-up including repeated autofluorescence
endoscopy and biopsies on a 6 months basis in case of low grade dysplasia or on a one year
basis in patients without dysplasia.
Stratifications factors for randomization are: Center, occupational exposure to respiratory
carcinogens, presence of a bronchial low dysplastic lesion versus absence of dysplasia.
Bronchial biopsies samples will be centrally reviewed by a panel of Pathologists.
After 36 months follow-up, each patient from the two groups will be subjected to a final
autofluorescence endoscopy and biopsy and a Spiral Chest Xray.
The final analysis will compare between the two groups :
1. The probability of progression from an initially identified low grade lesion to a high
grade lesion
2. The probability of respiratory epithelial tract progression assessed by the occurrence
of a lung cancer or high grade lesion.
3. The characteristics of lung cancers detected in each arm
4. In both arm, the influence of risk factors and persistent exposure to tobacco on lesion
evolutivity.
First inclusion into the trial : July 2002, End of recruitment December 2005, End of follow-
up : december 2008.
An ancillary study analysing the performances of fibered confocal fluorescence microscopy
has been started in december 2005 after IRB/ethical comity approval. This ancillary study is
only performed at the Rouen University Hospital Center.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04741958 -
Role of Ultrasound Guided Peripheral Thoracic Tumors
|
N/A | |
Recruiting |
NCT04556344 -
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer
|
N/A | |
Terminated |
NCT03306693 -
Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers
|
N/A | |
Completed |
NCT04751552 -
Erector Spinae Block for Thoracoscopic Surgery
|
N/A | |
Not yet recruiting |
NCT06104774 -
The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery
|
N/A | |
Completed |
NCT05770869 -
mHealth ALIBIRD: A Digital Health Care Model
|
N/A | |
Active, not recruiting |
NCT04589247 -
Improving Cancer Symptom Management
|
||
Not yet recruiting |
NCT04133337 -
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
|
Phase 1/Phase 2 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Completed |
NCT02188563 -
A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers
|
N/A | |
Completed |
NCT03134872 -
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
|
Phase 3 | |
Not yet recruiting |
NCT04371796 -
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
|
Phase 2 | |
Completed |
NCT00437372 -
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
|
Phase 1 | |
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04862780 -
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04776447 -
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
|
Phase 2 | |
Recruiting |
NCT05988736 -
Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients.
|
N/A | |
Not yet recruiting |
NCT06376084 -
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
|